Compile Data Set for Download or QSAR
Report error Found 73 Enz. Inhib. hit(s) with all data for entry = 50008334
TargetCytochrome P450 3A4(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 0.600nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50335377(N-Pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin...)
Affinity DataIC50: 1.80nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 2nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143388(US9682953, 20.A-13)
Affinity DataIC50: 2.20nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 2.20nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 2.40nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM81356(PF-3845, 10 | US20240308985, Comparator TableD2.2)
Affinity DataIC50: 2.60nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143449(US9682953, 20.A-20 | US9682953, 20.A-19)
Affinity DataIC50: 2.60nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143375(US9682953, 20.A-12 | US9682953, 20.A-11)
Affinity DataIC50: 2.60nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 2.70nMAssay Description:Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 3nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143267(US9682953, 2.B-15)
Affinity DataIC50: 3nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 3.40nMAssay Description:Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143293(US9682953, 4.A-3)
Affinity DataIC50: 4nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 4.60nMAssay Description:Inhibition of CYP2C19 in human liver microsomes using (S)-mephenytoin as substrate preincubated for 5 mins followed by NADPH cofactor addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 5nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143210(US9682953, 2.A-22)
Affinity DataIC50: 5.10nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM23120(CHEMBL177577 | 7-phenyl-1-[5-(pyridin-2-yl)-1,3-ox...)
Affinity DataIC50: 5.20nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50335377(N-Pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin...)
Affinity DataIC50: 5.70nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143208(US9682953, 2.A-19)
Affinity DataIC50: 6nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 6.20nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 6.5nMAssay Description:Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50518212(CHEMBL4435842)
Affinity DataIC50: 6.60nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM50518212(CHEMBL4435842)
Affinity DataIC50: 6.70nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143267(US9682953, 2.B-15)
Affinity DataIC50: 9nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143402(US9682953, 20.A-16 | US9682953, 20.A-15)
Affinity DataIC50: 9nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 9.10nMAssay Description:Inhibition of CYP2C19 in human liver microsomes using (S)-mephenytoin as substrate preincubated for 5 mins followed by NADPH cofactor addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 9.20nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 9.20nMAssay Description:Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 10nMAssay Description:Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 10nMAssay Description:Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate preincubated for 5 mins followed by NADPH cofactor addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143130(US9682953, 2.A-1)
Affinity DataIC50: 10nMAssay Description:Inhibition of human transmembrane domain deficient FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM81356(PF-3845, 10 | US20240308985, Comparator TableD2.2)
Affinity DataIC50: 12nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 12nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate preincubated for 5 mins followed by NADPH cofactor addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP2C19 in human liver microsomes using (S)-mephenytoin as substrate preincubated for 5 mins followed by NADPH cofactor addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetFatty-acid amide hydrolase 1 [30-579](Rat)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143355(US9682953, 20.A-1)
Affinity DataIC50: 13nMAssay Description:Inhibition of rat FFAH expressed in Escherichia coli using AAMCA as substrate incubated for 1 min measured for 50 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP2C19 in human liver microsomes using (S)-mephenytoin as substrate preincubated for 5 mins followed by NADPH cofactor addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143359(US9682953, 20.A-3)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143373(US9682953, 20.A-10 | US9682953, 20.A-9)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Advinus Therapeutics

Curated by ChEMBL
LigandPNGBDBM143362(US9682953, 20.A-5)
Affinity DataIC50: 13nMAssay Description:Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate preincubated for 5 mins followed by NADPH cofactor addition and me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
Displayed 1 to 50 (of 73 total ) | Next | Last >>
Jump to: